Impact of COVID-19 on heart rate variability in post-COVID individuals compared to a control group.

Publication date: Dec 28, 2024

This study investigated the impact of mild COVID-19 on HRV in groups stratified by time after infection and to compare to a healthy group of the same age without previous virus infection and without need of hospitalization. This is a cross-sectional study. We divided the sample into four groups: control group (CG) (n = 31), group 1 (G1): ≤6 weeks (n = 34), group 2 (G2): 2-6 months (n = 30), group 3 (G3): 7-12 months (n = 35) after infection. For HRV analysis, we used the indices of linear (time and frequency domain) and non-linear analysis. For comparisons between groups, ANOVA one way test or Kruskal-Wallis was used according to the data distribution. The effect size was calculated based on Cohen’s d or η. Simple and multiple linear regressions were performed to investigate the interaction between clinical outcomes and HRV parameters. A total of 130 individuals were included. Groups G1 and G2 showed less parasympathetic modulation when compared to CG (p 

Open Access PDF

Concepts Keywords
Covid Adult
G3 Aged
Hospitalization Autonomic nervous system
Virus COVID-19
COVID-19
Cross-Sectional Studies
Female
Heart Rate
Heart rate variability
Humans
Male
Middle Aged
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH virus infection
disease MESH Long Covid
disease MESH SD1
disease MESH hypertension
disease MESH dyslipidemia
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Coenzyme M
disease MESH sore throat
drug DRUGBANK Oxygen
disease MESH critical illness
disease MESH myocardial infarction
disease IDO history
disease MESH heart disease
disease MESH unstable angina
disease MESH diabetes mellitus
disease MESH chronic obstructive pulmonary disease
disease MESH neoplasms
disease MESH cognitive impairment
disease MESH cardiac arrhythmias
disease MESH respiratory diseases
disease MESH inflammation
disease MESH neurological disorders
drug DRUGBANK Ethanol
disease MESH dyspnea
disease MESH ageusia
disease MESH anosmia
disease MESH hair loss
disease MESH memory loss
disease MESH anxiety
drug DRUGBANK Caffeine
drug DRUGBANK Nicotine
disease IDO process
drug DRUGBANK Methionine
disease MESH Overweight
disease MESH Obesity
drug DRUGBANK Levothyroxine
disease IDO symptom
drug DRUGBANK Albendazole
drug DRUGBANK Isoxaflutole
disease MESH physiological stress
disease MESH sinus arrhythmia
disease MESH dysautonomia
disease IDO blood
pathway REACTOME Immune System
disease IDO replication
disease MESH cardiovascular disease
disease MESH causality
drug DRUGBANK L-Asparagine
disease MESH dengue
disease IDO immunodeficiency
disease MESH influenza
disease MESH syndrome
disease MESH ischemia
disease MESH pneumonia
drug DRUGBANK Imidacloprid
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)